1
EXHIBIT 10.131
AMENDMENT No. 2
THIS AMENDMENT (the "Amendment") is made and entered into effective
as of 11 December, 2000 (the "Effective Date"), by and between Axys
PHARMACEUTICALS, INC., a Delaware corporation having its principal place of
business at 000 Xxxxxxx Xxx, Xxxxx Xxx Xxxxxxxxx, XX 00000 ("Axys"), and AVENTIS
PHARMACEUTICALS PRODUCTS INC. (FORMERLY KNOWN as XXXXX-XXXXXXX XXXXX
PHARMACEUTICALS INC.), a Delaware corporation having its principal place of
business at Xxxxx 000-000, Xxxxxxxxxxx, XX 00000 ("APPI"). Axys and APPI may be
referred to herein as a "Party" or, collectively, as "Parties".
RECITALS
A. Under a Collaborative Research and License Agreement dated 11
December 1998, as amended by Amendment No. 1 dated 2 June 2000 (the "First
Amendment") (as so amended, the "Agreement"), Axys and APPI agreed to
collaborate in the discovery, development and commercialization of Cathepsin S
inhibitors for use in the prevention and/or treatment of certain human diseases.
B. Pursuant to Article 11.10 of the Agreement, the parties desire to
amend the Agreement to provide for an extension of the Research Term as defined
in Article 1.38 of the Agreement and to modify the milestone payments set forth
in Article 6.3 of the Agreement. During the extended Research Term, the parties
intend to pursue the Research Plan, as modified by the JRC as provided in
Article 1.36 of the Agreement, which modified plan generally provides for a
reallocation of the work in the Research Plan between Axys and APPI, including
adjustment of the Parties' research commitments, with the goal of nominating
multiple compounds for EDC during the Research Term.
NOW, THEREFORE, IN CONSIDERATION OF THE VARIOUS PROMISES AND UNDERTAKINGS
SET FORTH HEREIN, AXYS AND APPI AGREE AS FOLLOWS:
1. AMENDMENT OF THE AGREEMENT
The Parties hereby agree to amend the terms of the Agreement as provided
below. To the extent that the Agreement is explicitly amended by this Amendment,
the terms of the Amendment will control where the terms of the Agreement are
contrary to or conflict with the following provisions. Where the Agreement is
not explicitly amended, the terms of the Agreement will remain in force.
Capitalized terms used in this Amendment that are not otherwise defined herein
shall have the same meanings as such terms are defined in the Agreement.
2. AMENDMENT OF ARTICLE 1.38 OF THE AGREEMENT.
Article 1.38 of the Agreement is hereby amended and restated to read in
full as follows:
The Registrant has requested that portions of this exhibit be granted
confidential treatment.
1
2
"1.38 "RESEARCH TERM" means the period during which the Parties
shall conduct the Research, commencing on the Effective Date and
terminating upon either: (i) June 11, 2001; (ii) such later date as
the parties have agreed to extend the Research Term pursuant to
Section 2.10; or (iii) such date as of which this Agreement is
terminated pursuant to Section 10.2 or 10.3."
3. AMENDMENT OF ARTICLE 2.3 OF THE AGREEMENT. (a) The fifth sentence of
Article 2.3 of the Agreement is hereby amended and restated to read in full as
follows:
"Commencing upon the Effective and continuing through December 10,
0000, Xxxx shall commit an average of twelve (12) FTEs in its employ
to conduct Axys' obligations under the Research Plan."
(b) A the following new sentence is hereby added as the sixth sentence of
Article 2.3 of the Agreement.
"Commencing on December 11, 2000 and continuing through the
remainder of the Research Term, Axys shall commit an average of two
(2) FTEs in its employ to conduct Axys' obligations under the
Research Plan."
4. AMENDMENT OF ARTICLE 2.10 OF THE AGREEMENT. Article 2.10 of the Agreement
is hereby amended and restated to read in full as follows:
"From time to time, Axys and APPI may agree to further extensions of
the Research Term. Any such extensions shall be for the period of
time agreed to by the Parties and shall be evidenced by a written
amendment to this Agreement. At the end of the Research Term,
whether extended or not, all obligations of the Parties to conduct
any further Research activities shall terminate, but the other
rights and obligations under this Agreement shall not otherwise be
affected."
5. AMENDMENT OF ARTICLE 6.3(A) OF THE AGREEMENT. The milestone events and
payment amounts listed in Article 6.3(a) under the heading entitled "Preclinical
Payments" are hereby amended and restated to read in full as follows:
"Milestone Event Payment Amount
---------------- --------------
PRECLINICAL PAYMENTS:
First demonstration of Proof of Concept in **
an animal model for any Indication
* Confidential treatment has been requested by the Registrant.
2
3
"Milestone Event Payment Amount
---------------- --------------
First satisfaction of the EDC-C Criteria **
for any Indication
Satisfactory evidence of dose-dependent **
invariant chain accumulation in mouse
splenocytes after po administration of
an Active Compound at plasma levels
consistent with cellular inhibition of invariant
chain cleavage
First satisfaction of EDC Criteria by an orally **
bioavailable Collaboration Compound
First satisfaction of NCE Nomination Criteria **
for any Indication
The above milestone payments shall be made only once."
6. MISCELLANEOUS
The amendments set out in this Amendment shall have effect as of 11
December 2000. Except as expressly modified by this Amendment, all of the terms
and conditions of the Agreement shall remain in full force and effect. This
Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.
IN WITNESS WHEREOF, the Parties have executed this Amendment in duplicate
originals by their authorized officers as of the date and year first above
written.
AVENTIS PHARMACEUTICALS PRODUCTS INC.
By: /s/ XXXX ZUMWOD
------------------------------
Title: Vice President,
---------------------------
AXYS PHARMACEUTICALS, INC.
By: /s/ XXXXXXX X. XXXXXX
------------------------------
Title: Sr. Vice President
---------------------------
* Confidential treatment has been requested by the Registrant.
3
